{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T02:55:58Z","timestamp":1777949758145,"version":"3.51.4"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Systemic juvenile idiopathic arthritis-associated lung disease (sJIA-LD) is a rare, potentially fatal complication of sJIA, often accompanied by pulmonary hypertension (PHTN) and macrophage activation syndrome (MAS). The underlying pathophysiology remains poorly understood and optimal management strategies have yet to be established. Recent retrospective data suggest that combination therapy with cyclophosphamide (CYC) and rituximab (RTX) may be effective in children with severe or life-threatening manifestations of rheumatic disease. Yet, literature on combination therapy in sJIA-LD is lacking.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We describe two pediatric cases of sJIA-LD complicated by PHTN and recurrent episodes of MAS. Both patients remained refractory to conventional sJIA therapies, necessitating escalation with combination CYC\u2013RTX.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Following combination CYC\u2013RTX therapy, both patients demonstrated marked clinical improvement, including resolution of hyperferritinemia, normalization of acute phase reactants, and recovery of hepatic function profiles. Patient 1 experienced a reduction in supplemental oxygen requirement from 4 liters per minute (LPM) to 0.5 LPM nocturnally as well as improved PHTN measures: mean pulmonary arterial pressure decreased from 47 to 25 mmHg, and pulmonary vascular resistance decreased from 11.1 to 4.3 Wood units. Patient 2 experienced improved height velocity from &amp;lt;3rd percentile to &amp;gt;10th percentile and weaned off all therapies. Daily prednisone requirement for patient 1 decreased from 1 to &amp;lt;0.2 mg\/kg\/day. Chest computed tomography showed notable improvements in ground-glass opacities and septal and pleural thickening in both patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Combination therapy with CYC and RTX may represent a valuable therapeutic approach in refractory sJIA complicated by lung disease, particularly in patients with concomitant MAS or PHTN.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1798455","type":"journal-article","created":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T04:25:19Z","timestamp":1777868719000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Treatment of refractory lung disease in systemic juvenile idiopathic arthritis with cyclophosphamide and rituximab combination therapy"],"prefix":"10.3389","volume":"17","author":[{"given":"William J.","family":"Freeman","sequence":"first","affiliation":[{"name":"Department of General Pediatrics, Hofstra Northwell School of Medicine, Steven and Alexandra Cohen Children\u2019s Medical Center of New York","place":["New Hyde Park, NY, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eileen C.","family":"Rife","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Pediatrics, University of Alabama at Birmingham (UAB) Heersink School of Medicine, Children\u2019s of Alabama","place":["Birmingham, AL, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Randy Q.","family":"Cron","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Pediatrics, University of Alabama at Birmingham (UAB) Heersink School of Medicine, Children\u2019s of Alabama","place":["Birmingham, AL, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/art.42037","article-title":"2021 American College of Rheumatology guideline for the treatment of juvenile idiopathic arthritis: Therapeutic approaches for oligoarthritis, temporomandibular joint arthritis, and systemic juvenile idiopathic arthritis","volume":"74","author":"Onel","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2024-225851","article-title":"EULAR\/PReS recommendations for the diagnosis and management of Still\u2019s disease, comprising systemic juvenile idiopathic arthritis and adult-onset Still\u2019s disease","volume":"83","author":"Fautrel","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/acr.25234","article-title":"Disease course, treatments, and outcomes of children with systemic juvenile idiopathic arthritis\u2013associated lung disease","volume":"76","author":"Huang","year":"2024","journal-title":"Arthritis Care Res"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s40272-023-00593-8","article-title":"Diagnosis and management of the systemic juvenile idiopathic arthritis patient with emerging lung disease","volume":"25","author":"Towe","year":"2023","journal-title":"Pediatr Drugs"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2022.2095431","article-title":"Refractory systemic onset juvenile idiopathic arthritis: Current challenges and future perspectives","volume":"54","author":"Ambler","year":"2022","journal-title":"Ann Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780401019","article-title":"Trial of intravenous pulse cyclophosphamide and methylprednisolone in the treatment of severe systemic-onset juvenile rheumatoid arthritis","volume":"40","author":"Wallace","year":"1997","journal-title":"Arthritis Rheum"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/acr.25348","article-title":"2023 American College of Rheumatology (ACR)\/American College of Chest Physicians (CHEST) guideline for the treatment of interstitial lung disease in people with systemic autoimmune rheumatic diseases","volume":"76","author":"Johnson","year":"2024","journal-title":"Arthritis Care Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1159\/000547717","article-title":"Comparative efficacy of oral and intravenous cyclophosphamide in the treatment of connective tissue disease-associated interstitial lung disease and analysis of its influencing factors: A clinical trial","volume":"187","author":"Liu","year":"2025","journal-title":"Int Arch Allergy Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2013.02.008","article-title":"Using cyclophosphamide in inflammatory rheumatic diseases","volume":"24","author":"Brummaier","year":"2013","journal-title":"Eur J Intern Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.128.6.2453","article-title":"Suppression of human B lymphocyte function by cyclophosphamide","volume":"128","author":"Cupps","year":"1982","journal-title":"J Immunol Baltim Md 1950"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.937561","article-title":"Treating autoimmune-related interstitial lung disease with B cell depletion","volume":"9","author":"Liossis","year":"2022","journal-title":"Front Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/art.41073","article-title":"Systemic juvenile idiopathic arthritis\u2013associated lung disease: Characterization and risk factors","volume":"71","author":"Schulert","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.70095","article-title":"Safety and effectiveness of combination rituximab and cyclophosphamide therapy for treating pediatric patients with severe manifestations of rheumatic disease","volume":"7","author":"Rife","year":"2025","journal-title":"ACR Open Rheumatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-061813-012806","article-title":"Pathogenesis of macrophage activation syndrome and potential for cytokine-directed therapies","volume":"66","author":"Schulert","year":"2015","journal-title":"Annu Rev Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12123095","article-title":"Lung involvement in systemic juvenile idiopathic arthritis: A narrative review","volume":"12","author":"Petrongari","year":"2022","journal-title":"Diagnostics"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.132508","article-title":"Th17 reprogramming of T cells in systemic juvenile idiopathic arthritis","volume":"5","author":"Henderson","year":"2020","journal-title":"JCI Insight"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2013.00469","article-title":"Regulation of interferon gamma signaling by suppressors of cytokine signaling and regulatory T cells","volume":"4","author":"Larkin","year":"2013","journal-title":"Front Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2008.01.011","article-title":"Rituximab-induced B cell depletion in autoimmune diseases: Potential effects on T cells","volume":"127","author":"Liossis","year":"2008","journal-title":"Clin Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2025.101577","article-title":"Single-cell landscape of immunological responses in patients with juvenile idiopathic arthritis","volume":"12","author":"Liu","year":"2025","journal-title":"Genes Dis"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2026.01.021","article-title":"Clinically validated assay for rapid determination of type I and type II interferon activity in systemic inflammatory diseases","author":"Lam","year":"2026","journal-title":"J Allergy Clin Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2026.1730688","article-title":"Divergent roles of serum CXCL9 as a biomarker in ILD and COPD: A comparative study","volume":"17","author":"Yin","year":"2026","journal-title":"Front Pharmacol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0241719","article-title":"CXCL9, CXCL10, and CXCL11; biomarkers of pulmonary inflammation associated with autoimmunity in patients with collagen vascular diseases\u2013associated interstitial lung disease and interstitial pneumonia with autoimmune features","volume":"15","author":"Kameda","year":"2020","journal-title":"PLoS One"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa634","article-title":"Clinical significance of interleukin-18 for the diagnosis and prediction of disease course in systemic juvenile idiopathic arthritis","volume":"60","author":"Mizuta","year":"2021","journal-title":"Rheumatology"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2012.11.081","article-title":"Differentiating macrophage activation syndrome in systemic juvenile idiopathic arthritis from other forms of hemophagocytic lymphohistiocytosis","volume":"162","author":"Lehmberg","year":"2013","journal-title":"J Pediatr"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-017-2993-y","article-title":"Clinical utility of soluble interleukin-2 receptor in hemophagocytic syndromes: A systematic scoping review","volume":"96","author":"Lin","year":"2017","journal-title":"Ann Hematol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/art.43421","article-title":"Krebs von den Lungen-6 (KL-6) as a potential diagnostic biomarker of lung disease in pediatric systemic juvenile idiopathic arthritis: Preliminary findings from a multisite US cohort [abstract","volume":"77","author":"Rife","year":"2025","journal-title":"Arthritis Rheumatol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-019-04485-4","article-title":"Serum KL-6 level as a biomarker of interstitial lung disease in childhood connective tissue diseases: A pilot study","volume":"40","author":"Kilinc","year":"2020","journal-title":"Rheumatol Int"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.4046\/trd.2025.0134","article-title":"Serum Krebs von den Lungen-6 level as a reflecting biomarker in patients with interstitial lung abnormalities","volume":"89","author":"Kang","year":"","journal-title":"Tuberc Respir Dis"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.medcli.2025.107340","article-title":"The utility of lung ultrasound and KL-6 values for the screening of rheumatoid arthritis-associated interstitial lung disease: An exploratory study","volume":"166","author":"Casafont-Sol\u00e9","year":"2026","journal-title":"Med Clin (Barc)"},{"key":"B30","article-title":"International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: Second revision, Edmonton, 2001","volume":"31","author":"Petty","year":"2004","journal-title":"J Rheumatol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/art.39332","article-title":"2016 classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: A European League Against Rheumatism\/American College of Rheumatology\/Paediatric Rheumatology International Trials Organisation collaborative initiative","volume":"68","author":"Ravelli","year":"2016"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.11048","article-title":"Ferritin to erythrocyte sedimentation rate ratio: Simple measure to identify macrophage activation syndrome in systemic juvenile idiopathic arthritis","volume":"1","author":"Eloseily","year":"2019","journal-title":"Acr Open Rheumatol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1604648","article-title":"Efficacy and safety of ruxolitinib in adult patients with refractory rheumatic disease-associated macrophage activation syndrome","volume":"16","author":"Li","year":"2025","journal-title":"Front Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-216983","article-title":"Effectiveness and safety of ruxolitinib for the treatment of refractory systemic idiopathic juvenile arthritis like associated with interstitial lung disease: A case report","volume":"81","author":"Bader-Meunier","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keae589","article-title":"The place of JAK inhibitors in systemic juvenile idiopathic arthritis with lung disease: French experience","volume":"64","author":"C\u00f4te","year":"2025","journal-title":"Rheumatology"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1521837113","article-title":"Autoinflammation and autoimmunity in systemic juvenile idiopathic arthritis","volume":"112","author":"Nigrovic","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1002\/art.41107","article-title":"Innately adaptive or truly autoimmune: Is there something unique about systemic juvenile idiopathic arthritis","volume":"72","author":"Kessel","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2402073","article-title":"Juvenile idiopathic arthritis","volume":"393","author":"Sandborg","year":"2025","journal-title":"N Engl J Med"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-023-01042-z","article-title":"Treatment of systemic juvenile idiopathic arthritis","volume":"19","author":"Hinze","year":"2023","journal-title":"Nat Rev Rheumatol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1798455\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T04:25:23Z","timestamp":1777868723000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1798455\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,4]]},"references-count":39,"alternative-id":["10.3389\/fimmu.2026.1798455"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1798455","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,4]]},"article-number":"1798455"}}